C61
Conditions
Interventions
Group 1: Strength-endurance training: 2x per week supervised about 75min, warming-up, 7 different strength exercises (2-4 series á 8-12 repetitions at 75 % of 1RM) + impact-training, cooling-down
Grou
Sponsors
Deutsche Sporthochschule zu Köln
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Prostate cancer patients who have received hormone therapy continuously at least over a period of 3 months and a maximum of 12 months. The treatment needs to be continue for at least one year. Half of the patients ( n = 30) received Leuprone® , the other half ( n = 30) alternative hormonal therapies. Serum testosterone levels 18 singed informed consent
Exclusion criteria
Exclusion criteria: ongoing medication with tricyclic antidepressants and duloxetine (Yentreve) WHO / ECOG performance status> 2 Planned OP Life expectancy <6 months All disease situations that do not allow a sporting activity, in particular: Clinically manifest heart failure (NYHA III-IV) Respiratory partial or global failure Durable thrombocytopenia <10,000 / ul, for example, Autoimmunthrombozytopenien intractable. Congenital or acquired thrombocytopenia or any coagulation disorder. Symptomatic CHD (possibly performing exercise ECG is recommended) Severe intractable hypertension Not adjustable COPD Uncontrolled cerebral convulsions CNS metastases Medical or mental state that leads the investigator to not allowing the patient to participate in the study. or a legally binding signature of the consent form does Unwillingness to storage and transfer of personal data in the context of the study protocol. Participation in another sport-study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Strength: dynamically on a isokinetic dynamometer Measurements: Baseline, 3, 6 and 12 months, and 6 and 12 months follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| Endurance with a 30/15 Test on a bicycle ergometer Quality of life via a questionnaire (EORTC QLQ - C30 and PR25) Fatigue via a questionnaire (MFI) Body composition via BIA (bioelectrical impedance analysis) erectile dysfunction via a questionnaire (IIEF) bone pain via a questionnaire (FACT- BP) Activity level via questionnaires (QPAQ and KAS ) BMI BMD via DXA scan PSA and testosterone value Measurement timing: See primary endpoint, except bone density BMD measurements: baseline, after 12 months and 12 months follow -up | — |
Countries
Germany
Contacts
Public ContactAnja Großek
Deutsche Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin
Outcome results
None listed